{
    "clinical_study": {
        "@rank": "67214", 
        "arm_group": [
            {
                "arm_group_label": "erythropoietin, perinatal asphyxia,", 
                "arm_group_type": "Active Comparator", 
                "description": "Treatment group"
            }, 
            {
                "arm_group_label": "Normal saline, perinatal asphyxia", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Normal saline on alternate days for 5 doses starting from first 6 hours of life"
            }
        ], 
        "brief_summary": {
            "textblock": "Whether Erythropoietin improves the neurological outcomes of neonates with perinatal\n      asphyxia."
        }, 
        "brief_title": "Neuroprotective Role of Erythropoietin in Perinatal Asphyxia", 
        "completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Perinatal Asphyxia", 
        "condition_browse": {
            "mesh_term": "Asphyxia"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Babies with severe perinatal asphyxia with moderate to severe HIE in the immediate\n             neonatal period\n\n        Exclusion Criteria:\n\n          -  Babies with congenital malformations\n\n          -  Small for gestational age babies\n\n          -  Babies with chromosomal anomalies"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "12 Hours", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 27, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02002039", 
            "org_study_id": "Erythropoietin 01"
        }, 
        "intervention": {
            "arm_group_label": [
                "erythropoietin, perinatal asphyxia,", 
                "Normal saline, perinatal asphyxia"
            ], 
            "description": "500 units /kg /day every other day for 5 doses", 
            "intervention_name": "Erythropoietin", 
            "intervention_type": "Drug", 
            "other_name": "erhthropoietin beta"
        }, 
        "intervention_browse": {
            "mesh_term": "Epoetin Alfa"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Perinatal asphyxia", 
            "erythropoietin"
        ], 
        "lastchanged_date": "April 1, 2014", 
        "location": {
            "contact": {
                "email": "mbhat47@rediffmail.com", 
                "last_name": "Mushtaq Bhat, MD"
            }, 
            "facility": {
                "address": {
                    "city": "Srinagar", 
                    "country": "India", 
                    "state": "Jammu and kashmir"
                }, 
                "name": "Sheri-Kashmir Institute of Medical Sciences"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "India"
        }, 
        "number_of_arms": "2", 
        "official_title": "Erythropoietin in Perinatal Asphyxia: A Randomized Placebo Controlled Trial", 
        "other_outcome": {
            "measure": "Hearing impairment", 
            "safety_issue": "Yes", 
            "time_frame": "12-18 months"
        }, 
        "overall_contact": {
            "email": "mbhat47@rediffmail.com", 
            "last_name": "Dr. Mushtaq Bhat, MD"
        }, 
        "overall_official": [
            {
                "affiliation": "SKIMS", 
                "last_name": "Feroz Shaheen, MD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "SKIMS", 
                "last_name": "Prof. WAjid Ali", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "India: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Neurological outcomes including cerebral palsy, any gross motor delay, Hearing impairment", 
            "measure": "Death and or disability at 12-18 months of life", 
            "safety_issue": "Yes", 
            "time_frame": "12-18 months after birth"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02002039"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Sheri Kashmir Institute of Medical Sciences", 
            "investigator_full_name": "Dr.Mushtaq", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Gross motor delay", 
            "safety_issue": "Yes", 
            "time_frame": "12-18 months"
        }, 
        "source": "Sheri Kashmir Institute of Medical Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sheri Kashmir Institute of Medical Sciences", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}